A Comparative Study on the Prevalence of Helicobacter pylori Infection in Patients with Central Serous Chorioretinopathy versus a Control Population

中心性浆液性脉络膜视网膜病变患者与对照人群幽门螺杆菌感染率的比较研究

阅读:1

Abstract

PURPOSE: This study investigates the association between Helicobacter pylori (H. pylori) infection and Central Serous Chorioretinopathy (CSCR) by comparing the prevalence of H. pylori in CSCR patients with that in a control group without CSCR. PATIENTS AND METHODS: A 3-month cross-sectional observational and interventional study was conducted involving 40 patients diagnosed with CSCR, divided into two groups: Group A (20 patients with recurrent CSCR) and Group B (20 patients with a single CSCR episode). Both groups were matched with a control group of 40 individuals without CSCR. All participants underwent comprehensive ophthalmologic examinations and optical coherence tomography (OCT) to confirm CSCR. Patients who tested positive for H. pylori received a 14-day standard eradication therapy. Post-treatment, visual acuity was assessed, and potential side effects were monitored. RESULTS: In Group A (recurrent CSCR), 15 out of 20 patients (75%) tested positive for H. pylori, while in Group B (single episode), 8 out of 20 patients (40%) tested positive. The control group had a prevalence of H. pylori of 12 out of 40 (30%). The differences in prevalence among the groups were statistically significant: Group A vs Control (p < 0.001), Group B vs Control (p = 0.02), and Group A vs Group B (p = 0.03). Post-treatment evaluation showed improved visual acuity and reduced recurrence rates in Group A patients who received H. pylori eradication therapy. However, some side effects associated with the treatment were also reported. CONCLUSION: The study highlights a significant association between H. pylori infection and central serous chorioretinopathy (CSCR), especially in recurrent cases. Identifying and treating H. pylori in CSCR patients may improve visual outcomes and aid in disease management. However, potential side effects of eradication therapy should be considered.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。